Before introducing the use of anti-vascular endothelial growth factor (anti-VEGF) agents in infants, clinical trials had confirmed the efficacy and safety of ablating the avascular peripheral retina to achieve the regression of preretinal neovascularization and prevent ensuing fibrovascular retinal detachments [2]. Here, VEGFA is linked to retinal detachment.